Cyclooxygenase-2 expression: Does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma?


Sozen S., Gurocak S., ERDEM O. A., Acar C., Kordan Y., AKYOL G., ...More

International Urology and Nephrology, vol.40, no.2, pp.295-301, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 2
  • Publication Date: 2008
  • Doi Number: 10.1007/s11255-007-9268-9
  • Journal Name: International Urology and Nephrology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.295-301
  • Keywords: cyclooxygenase-2, immunohistochemistry, prognosis, renal cell carcinoma, tumorigenesis, ENDOTHELIAL GROWTH-FACTOR, PROGNOSTIC INDICATORS, MATRIX METALLOPROTEINASE-2, MULTIVARIATE-ANALYSIS, COX-2 EXPRESSION, CANCER, PROGRESSION, APOPTOSIS, SURVIVAL, DISEASE
  • Gazi University Affiliated: Yes

Abstract

Objectives: The purpose of this study was to evaluate the correlation between the levels of cyclooxygenase- 2 (COX-2) expression with clinicopathologic features and determine the impact on prognosis in patients with renal cell carcinoma (RCC). Methods: Expression of COX-2 was evaluated immunohistochemically in RCC tissues from 62 patients who underwent radical nephrectomy between 1996 and 2004. Percentage of COX-2 staining was scored as 0 (negative), 1 (1-24%), 2 (25-49%), 3 (50-74%), and 4 (75-100%). Immunohistochemical COX-2 staining score (ISS) was defined as summation of intensity and percentage of COX-2 staining. Results: Twenty-seven patients (43.5%) with a median follow-up of 47.8 (25-115) months stained positively for COX-2. COX-2 expression was positive in 37.1%, 50%, and 66.7% of patients with stages 1, 2, and 3, respectively (P = 0.46). Correlation between ISS and pathological stage was statistically significant (P = 0.005). Multivariate regression analysis revealed no clinicopathologic parameter as independent predictors of progression. Kaplan-Meier analysis revealed statistically significant different survival rates in tumor stage, grade, and ISS. Conclusion: Although COX-2 expression is not an independent predictor of progression in patients with RCC, patients with higher ISS values have significantly shorter progression-free survival rates. These results might be important to the clinician because positive COX-2 expression of a certain RCC might necessitate early adjuvant systemic therapy to delay the progression of RCC. For this reason, there is a need for innovative, prospective, and randomized studies in patients with positive COX-2 expression that will display the impact of systemic therapies in these patients. © Springer Science+Business Media B.V. 2008.